首 页   本刊简介  编委会  审稿专家  在线期刊  写作规范  广告合作  联系我们
您现在的位置:首页 => 在线期刊 => 2016年 6期 肝纤维化及肝硬化 => 肝纤维化及肝硬化 =>替比夫定治疗对慢性乙..
替比夫定治疗对慢性乙型肝炎和肝硬化患者血清可溶性红细胞补体受体1的影响
Influence of antiviral therapy with telbivudine on serum soluble complement receptor type 1 in patients with chronic hepatitis B or liver cirrhosis
文章发布日期:2016年05月06日  来源:  作者:王方,权作华,杨兴坤,等  点击次数:1109次  下载次数:296次

调整字体大小:

(此处下载失败可以在在线预览处保存副本或者右键另存为)

【摘要】:目的观察慢性乙型肝炎(CHB)和肝硬化患者经替比夫定抗病毒治疗3、6个月后血清可溶性红细胞补体受体1(sCR1)的变化,探讨替比夫定治疗对于sCR1水平的的影响。方法选择2013年1-6月在兰州军区兰州总医院安宁分院就诊的HBeAg阳性CHB、肝硬化患者57例,给予替比夫定抗病毒治疗,于治疗前和治疗后3、6个月抽静脉血,采用ELISA法检测sCR1。组内比较采用配对t检验。两组间比较采用独立样本t检验。结果替比夫定抗病毒治疗后,全部患者在治疗3、6个月时sCR1与对应的基线水平相比差异有统计学意义(t值分别为4.864、6.238,P值均<0.05)。CHB患者和肝硬化患者sCR1水平在治疗3、6个月时与对应的基线相比差异均有统计学意义(t值分别为3425、5468、4047、7378,P值均<0.05)。CHB患者血清sCR1水平在基线、治疗3、6个月均较肝硬化患者低,但两组间各时间点相比差异均无统计学意义(P值均>005)。结论HBeAg阳性CHB、肝硬化患者经替比夫定抗病毒治疗后血清sCR1水平显著下降。
【Abstract】:Abstract:ObjectiveTo investigate the changes in serum soluble complement receptor type 1 (sCR1) at 3 and 6 months after antiviral therapy with telbivudine in patients with chronic hepatitis B (CHB) or liver cirrhosis and the influence of telbivudine on serum sCR1 level. MethodsA total of 57 patients with HBeAg-positive CHB or liver cirrhosis were enrolled and given the antiviral therapy with telbivudine. Venous blood was collected before treatment and at 3 and 6 months after treatment, and enzyme-linked immunosorbent assay was used to measure serum sCR1 level. The paired t-test was used for comparison within one group. ResultsAt 3 and 6 months after the antiviral treatment with telbivudine, the serum sCR1 level changed significantly compared with corresponding baseline values (t=4.864 and 6.238, both P<0.05). The patients with CHB or liver cirrhosis showed significant changes in the serum sCR1 level at 3 and 6 months after treatment compared with corresponding baseline values (t=3425,5468,4047,7378 all P<0.05). The patients with CHB had a lower serum sCR1 level at baseline and at 3 and 6 months after treatment than those with liver cirrhosis, but the serum sCR1 level at each time point showed no significant differences between the two groups (all P=>005). ConclusionIn patients with HBeAg-positive CHB or liver cirrhosis, serum sCR1 level is reduced significantly after antiviral therapy with telbivudine.
【关键字】:肝炎,乙型,慢性;肝硬化;替比夫定;受体,补体
【Key words】:hepatitis B, chronic; liver cirrhosis; telbifvdine; receptors, complement
【引证本文】:王方, 权作华, 杨兴坤, 等. 替比夫定治疗对慢性乙型肝炎和肝硬化患者血清可溶性红细胞补体受体1的影响[J]. 临床肝胆病杂志, 2016, 32(6): 1118-1120.

地址:长春市东民主大街519号《临床肝胆病杂志》编辑部 邮编:130061 电话:0431-88782542/3542
临床肝胆病杂志 版权所有 Copyright © 2009 - 2013 Lcgdbzz.org. All Rights Reserv 吉ICP备10000617号

吉公网安备 22010402000041号